secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001558370-23-018276
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q3 revenue down 25% to $8.0M, net loss widens; FY guidance reiterated
-----------------------------------------------------------------------------

- Total revenue $8.0M (-25% YoY); core business revenue $6.6M (-33%).
- Net loss $11.3M vs $6.4M loss in Q3 2022; EBITDA loss $12.9M vs $7.1M.
- Cell therapy revenue $4.7M (-40%); drug discovery $1.9M (-5%).
- FY2023 guidance reaffirmed: total $34-36M, core $28-30M, SPL ~$6M.
- Cash & investments $208.7M; expect ~$200M year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023018276/0001558370-23-018276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023018276/mxct-20231108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer